OPWM
EGRX

Oak Point Wealth Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Oak Point Wealth Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$5K Hold
100
– – 0.01% 178
2017
Q4 		$5K Buy
+100
New +$5.57K ﹤0.01% 179

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Oak Point Wealth Management's EGRX Position: Q1 2018 in Review

Oak Point Wealth Management held its Eagle Pharmaceuticals, Inc. (EGRX) position steady in Q1 2018 at 100 shares worth $5K. The position accounts for 0.01% of the portfolio, ranked #178.

Oak Point Wealth Management first reported a position in EGRX in Q4 2017 and has held it in 2 quarters since. 174 funds tracked by Wall St. Rank hold EGRX as of Q1 2018.

  • Oak Point Wealth Management held 100 shares of Eagle Pharmaceuticals, Inc. worth $5K as of Q1 2018.
  • Oak Point Wealth Management left its Eagle Pharmaceuticals, Inc. share count unchanged in Q1 2018.
  • Eagle Pharmaceuticals, Inc. made up 0.01% of Oak Point Wealth Management's portfolio in Q1 2018, its #178 holding.
  • Oak Point Wealth Management first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2017 and has held it in 2 quarters since.
  • 174 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2018.

Based on Oak Point Wealth Management's 13F filing for Q1 2018, filed 30 Apr 2018.